Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Robot-assisted pancreaticoduodenectomy (RPD) has been gaining attention for its potential benefits in short-term surgical outcomes compared with open pancreaticoduodenectomy (OPD) in pancreatic cancer. However, the evidence of its long-term oncological efficacy is limited.
Methods: This retrospective study compared the long-term outcomes of RPD and OPD in patients with pancreatic cancer at Seoul National University Hospital between January 2015 and October 2023. Patients with stage III or IV disease and those who underwent open surgery were excluded. Propensity score matching (PSM) at a 1:2 ratio was performed based on sex, age, the American Society of Anesthesiologists (ASA) class, and initial resectability. The primary outcomes were overall survival (OS) and disease-free survival (DFS), and the secondary outcomes were postoperative recovery and complication rates.
Results: In total, 522 patients (82 RPD and 440 OPD) were reviewed, and 82 RPD and 164 matched OPD patients were analyzed after PSM. The mean age was 64.8 years in the RPD and 65.2 years in the matched OPD group; there were 51.2% male patients in the RPD and 52.4% in the OPD groups. After PSM, patients with RPDs showed better OS and DFS (5-year OS 58.2% vs. 32.3%, P = 0.001; 5-year DFS: 44.6% vs. 24.7%, P = 0.005). The R0 resection rates and harvested lymph node (LN) number were also comparable (RPD versus OPD: R0 resection rate 92.7% versus 90.9%, P = 0.809; harvested LNs 20.0 ± 7.3 versus 23.1 ± 11.5, P = 0.090). Additionally, patients with RPD had a shorter postoperative recovery time and relatively higher adjuvant therapy completion rate, although the difference was only marginally significant (91.6% vs. 75.4%, P = 0.062).
Conclusion: RPD is a feasible alternative to OPD, with potential advantages of early recovery without compromising long-term outcomes after PSM. However, further prospective studies are required to confirm these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287213 | PMC |
| http://dx.doi.org/10.1007/s00464-025-11833-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic reactive lymphoid hyperplasia diagnosed through post-ablation liver tumor biopsy.
Clin J Gastroenterol
September 2025
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Hepatic reactive lymphoid hyperplasia (RLH), also known as hepatic pseudolymphoma, is a rare benign condition that predominantly affects middle-aged-to-elderly women and is often associated with autoimmune disorders. The imaging features of hepatic RLH frequently mimic those of malignant hepatic tumors, such as hepatocellular carcinoma (HCC), cholangiocarcinoma, or metastatic liver tumors, making its diagnosis based solely on imaging modalities challenging, often leading to unnecessary surgical resection. However, the optimal diagnostic strategy for hepatic RLH remains controversial.
View Article and Find Full Text PDFDeciphering pancreatobiliary intraductal oncocytic papillary neoplasms: integrative analysis of histomorphologic patterns, immunophenotypic markers, and emerging molecular biomarkers.
World J Surg Oncol
September 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Dongcheng District, Beijing, 100730, China.
Purpose: We reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015-2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN's biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm.
Methods: English-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024.
ASO Visual Abstract: SPARC Expression Induces COL1A1/COL3A1 Representing Aggressive Molecular Cancer-Associated Fibroblast Signatures and CSF1-Mediated Cancer Invasion in Colorectal Cancer.
Ann Surg Oncol
September 2025
Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Deciphering disease-specific glycosylation: unraveling diabetes subtypes through serum glycopattern.
Anal Bioanal Chem
September 2025
Center for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, Jiangsu, China.
Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of diabetes that develops in adulthood, characterized by autoimmune destruction of pancreatic β-cells and subsequent insulin deficiency, akin to type 1 diabetes (T1D). Due to its shared genetic, immunological, and metabolic features with both T1D and type 2 diabetes (T2D), LADA is frequently misdiagnosed and inappropriately treated as T2D. To address this, we developed the A.
View Article and Find Full Text PDFGALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.
Pancreatology
August 2025
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, remains a therapeutic challenge. While GALNT4 (a member of the N-acetylgalactosaminyltransferases family) shows significant upregulation in PDAC cells, its precise oncogenic mechanisms remain poorly understood.
Methods: Bioinformatics analysis was performed to examine the expression of GALNT4 and MUC1 in pancreatic adenocarcinoma (PAAD) and to predict the glycosylation sites of MUC1.